Cargando…
Gaining an Understanding of Pneumocystosis in Wales
Pneumocystis pneumonia (PcP) is a serious complication of many significant immunocompromising conditions. Prior incidence estimates in Wales are based on PcP’s presentation in the HIV and transplant populations. The objectives were to describe the incidence of PcP in Wales using laboratory reporting...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302409/ https://www.ncbi.nlm.nih.gov/pubmed/37367596 http://dx.doi.org/10.3390/jof9060660 |
_version_ | 1785065038082473984 |
---|---|
author | Ayling-Smith, Jonathan Backx, Matthijs Grant, Elizabeth Dhillon, Rishi Duckers, Jamie Hood, Kerenza White, P. Lewis |
author_facet | Ayling-Smith, Jonathan Backx, Matthijs Grant, Elizabeth Dhillon, Rishi Duckers, Jamie Hood, Kerenza White, P. Lewis |
author_sort | Ayling-Smith, Jonathan |
collection | PubMed |
description | Pneumocystis pneumonia (PcP) is a serious complication of many significant immunocompromising conditions. Prior incidence estimates in Wales are based on PcP’s presentation in the HIV and transplant populations. The objectives were to describe the incidence of PcP in Wales using laboratory reporting measures and assess the impact of underlying immunosuppression cause on mortality. All positive PCR results for PcP between 2015 and 2018 were identified. The total number of unique positives with clinical and radiological correlation was 159 patients, a mean of 39.75 annually. The healthcare records of these patients were reviewed. The mortality at one month was 35.2% and 49.1% at one year. HIV remains the commonest cause of immunosuppression but has lower mortality than non-HIV conditions (12% vs. 59% at one year, p < 0.00001). Non-HIV conditions were categorised as life-threatening and non-life threatening but had a non-significant mortality (66% vs. 54%; p = 0.149), highlighting the negative impact of PcP. An incidence of PcP in Wales of 1.23–1.26 cases per 100,000 has been identified, 32–35% greater than the upper limit previously estimated. There is high mortality in non-HIV patients regardless of immunosuppression cause. A heightened awareness of PcP in these groups will hasten diagnosis and potentially improve mortality. |
format | Online Article Text |
id | pubmed-10302409 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103024092023-06-29 Gaining an Understanding of Pneumocystosis in Wales Ayling-Smith, Jonathan Backx, Matthijs Grant, Elizabeth Dhillon, Rishi Duckers, Jamie Hood, Kerenza White, P. Lewis J Fungi (Basel) Article Pneumocystis pneumonia (PcP) is a serious complication of many significant immunocompromising conditions. Prior incidence estimates in Wales are based on PcP’s presentation in the HIV and transplant populations. The objectives were to describe the incidence of PcP in Wales using laboratory reporting measures and assess the impact of underlying immunosuppression cause on mortality. All positive PCR results for PcP between 2015 and 2018 were identified. The total number of unique positives with clinical and radiological correlation was 159 patients, a mean of 39.75 annually. The healthcare records of these patients were reviewed. The mortality at one month was 35.2% and 49.1% at one year. HIV remains the commonest cause of immunosuppression but has lower mortality than non-HIV conditions (12% vs. 59% at one year, p < 0.00001). Non-HIV conditions were categorised as life-threatening and non-life threatening but had a non-significant mortality (66% vs. 54%; p = 0.149), highlighting the negative impact of PcP. An incidence of PcP in Wales of 1.23–1.26 cases per 100,000 has been identified, 32–35% greater than the upper limit previously estimated. There is high mortality in non-HIV patients regardless of immunosuppression cause. A heightened awareness of PcP in these groups will hasten diagnosis and potentially improve mortality. MDPI 2023-06-13 /pmc/articles/PMC10302409/ /pubmed/37367596 http://dx.doi.org/10.3390/jof9060660 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ayling-Smith, Jonathan Backx, Matthijs Grant, Elizabeth Dhillon, Rishi Duckers, Jamie Hood, Kerenza White, P. Lewis Gaining an Understanding of Pneumocystosis in Wales |
title | Gaining an Understanding of Pneumocystosis in Wales |
title_full | Gaining an Understanding of Pneumocystosis in Wales |
title_fullStr | Gaining an Understanding of Pneumocystosis in Wales |
title_full_unstemmed | Gaining an Understanding of Pneumocystosis in Wales |
title_short | Gaining an Understanding of Pneumocystosis in Wales |
title_sort | gaining an understanding of pneumocystosis in wales |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302409/ https://www.ncbi.nlm.nih.gov/pubmed/37367596 http://dx.doi.org/10.3390/jof9060660 |
work_keys_str_mv | AT aylingsmithjonathan gaininganunderstandingofpneumocystosisinwales AT backxmatthijs gaininganunderstandingofpneumocystosisinwales AT grantelizabeth gaininganunderstandingofpneumocystosisinwales AT dhillonrishi gaininganunderstandingofpneumocystosisinwales AT duckersjamie gaininganunderstandingofpneumocystosisinwales AT hoodkerenza gaininganunderstandingofpneumocystosisinwales AT whiteplewis gaininganunderstandingofpneumocystosisinwales |